Journal article 159 views 15 downloads
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study
David M. Williams
,
Barbara-Alex Alberts,
Asem Sharaf,
Giselle Sharaf,
Steve Bain
,
Atul Kalhan,
Thinzar Min
Diabetes Therapy
Swansea University Authors:
Steve Bain , Thinzar Min
-
PDF | Version of Record
This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Download (463.44KB)
DOI (Published version): 10.1007/s13300-024-01590-x
Abstract
IntroductionOral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice.MethodsPeople with T2...
Published in: | Diabetes Therapy |
---|---|
ISSN: | 1869-6953 1869-6961 |
Published: |
Springer Science and Business Media LLC
2024
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa66445 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2024-05-15T12:55:38Z |
---|---|
last_indexed |
2024-05-15T12:55:38Z |
id |
cronfa66445 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>66445</id><entry>2024-05-15</entry><title>Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>27cba511a4800fefddb6885ffffdb8b2</sid><firstname>Thinzar</firstname><surname>Min</surname><name>Thinzar Min</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-05-15</date><deptcode>MEDS</deptcode><abstract>IntroductionOral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice.MethodsPeople with T2D initiated on oral semaglutide in secondary care diabetes clinics at two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons for oral semaglutide initiation and changes in bodyweight, blood pressure, glycemic control, and lipid profiles over follow-up at 3–6 months, and at 6–12 months. Data were collected to determine the safety of oral semaglutide.ResultsSeventy-six patients were included, with a median age 59.3 [51.4–67.6] years, and 38 (50.0%) patients were female. The most common reasons for oral semaglutide were need for weight loss and improved glycemia (69.8%), and improved glycemia alone (25.0%). Oral semaglutide associated with significantly reduced bodyweight (− 3.3 kg), body mass index (BMI) (– 0.9 kg/m2), glycated hemoglobin (HbA1c) (− 11 mmol/mol), and total cholesterol (− 0.4 mmol/l) by 3–6 months follow-up. At 6–12 months, there was a significant reduction in systolic blood pressure (− 7.0 mmHg), in addition to sustained reductions in other metabolic parameters. By 12 months, 18 (23.6%) patients had discontinued the drug, largely resulting from gastrointestinal disturbance, but there were no serious events in this cohort.ConclusionsOral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group.</abstract><type>Journal Article</type><journal>Diabetes Therapy</journal><volume>0</volume><journalNumber/><paginationStart/><paginationEnd/><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1869-6953</issnPrint><issnElectronic>1869-6961</issnElectronic><keywords>Semaglutide; Glucagon-like peptide-1 receptor analogues; GLP-1; Type 2 diabetes; Weight loss; Real world</keywords><publishedDay>9</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-05-09</publishedDate><doi>10.1007/s13300-024-01590-x</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders>No funding was received for the preparation or publication of this manuscript.</funders><projectreference/><lastEdited>2024-06-12T16:28:46.7878354</lastEdited><Created>2024-05-15T13:54:14.9075142</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>David M.</firstname><surname>Williams</surname><orcid>0000-0001-9206-5837</orcid><order>1</order></author><author><firstname>Barbara-Alex</firstname><surname>Alberts</surname><order>2</order></author><author><firstname>Asem</firstname><surname>Sharaf</surname><order>3</order></author><author><firstname>Giselle</firstname><surname>Sharaf</surname><order>4</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>5</order></author><author><firstname>Atul</firstname><surname>Kalhan</surname><order>6</order></author><author><firstname>Thinzar</firstname><surname>Min</surname><order>7</order></author></authors><documents><document><filename>66445__30577__3062547a557b4c59ae61d726f60779f0.pdf</filename><originalFilename>66445.pdf</originalFilename><uploaded>2024-06-07T15:28:27.8966166</uploaded><type>Output</type><contentLength>474563</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
spelling |
v2 66445 2024-05-15 Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 27cba511a4800fefddb6885ffffdb8b2 Thinzar Min Thinzar Min true false 2024-05-15 MEDS IntroductionOral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice.MethodsPeople with T2D initiated on oral semaglutide in secondary care diabetes clinics at two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons for oral semaglutide initiation and changes in bodyweight, blood pressure, glycemic control, and lipid profiles over follow-up at 3–6 months, and at 6–12 months. Data were collected to determine the safety of oral semaglutide.ResultsSeventy-six patients were included, with a median age 59.3 [51.4–67.6] years, and 38 (50.0%) patients were female. The most common reasons for oral semaglutide were need for weight loss and improved glycemia (69.8%), and improved glycemia alone (25.0%). Oral semaglutide associated with significantly reduced bodyweight (− 3.3 kg), body mass index (BMI) (– 0.9 kg/m2), glycated hemoglobin (HbA1c) (− 11 mmol/mol), and total cholesterol (− 0.4 mmol/l) by 3–6 months follow-up. At 6–12 months, there was a significant reduction in systolic blood pressure (− 7.0 mmHg), in addition to sustained reductions in other metabolic parameters. By 12 months, 18 (23.6%) patients had discontinued the drug, largely resulting from gastrointestinal disturbance, but there were no serious events in this cohort.ConclusionsOral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group. Journal Article Diabetes Therapy 0 Springer Science and Business Media LLC 1869-6953 1869-6961 Semaglutide; Glucagon-like peptide-1 receptor analogues; GLP-1; Type 2 diabetes; Weight loss; Real world 9 5 2024 2024-05-09 10.1007/s13300-024-01590-x COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee No funding was received for the preparation or publication of this manuscript. 2024-06-12T16:28:46.7878354 2024-05-15T13:54:14.9075142 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science David M. Williams 0000-0001-9206-5837 1 Barbara-Alex Alberts 2 Asem Sharaf 3 Giselle Sharaf 4 Steve Bain 0000-0001-8519-4964 5 Atul Kalhan 6 Thinzar Min 7 66445__30577__3062547a557b4c59ae61d726f60779f0.pdf 66445.pdf 2024-06-07T15:28:27.8966166 Output 474563 application/pdf Version of Record true This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. true eng http://creativecommons.org/licenses/by/4.0/ |
title |
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study |
spellingShingle |
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study Steve Bain Thinzar Min |
title_short |
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study |
title_full |
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study |
title_fullStr |
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study |
title_full_unstemmed |
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study |
title_sort |
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study |
author_id_str_mv |
5399f4c6e6a70f3608a084ddb938511a 27cba511a4800fefddb6885ffffdb8b2 |
author_id_fullname_str_mv |
5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain 27cba511a4800fefddb6885ffffdb8b2_***_Thinzar Min |
author |
Steve Bain Thinzar Min |
author2 |
David M. Williams Barbara-Alex Alberts Asem Sharaf Giselle Sharaf Steve Bain Atul Kalhan Thinzar Min |
format |
Journal article |
container_title |
Diabetes Therapy |
container_volume |
0 |
publishDate |
2024 |
institution |
Swansea University |
issn |
1869-6953 1869-6961 |
doi_str_mv |
10.1007/s13300-024-01590-x |
publisher |
Springer Science and Business Media LLC |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science |
document_store_str |
1 |
active_str |
0 |
description |
IntroductionOral semaglutide improves cardiovascular risk factors in people with type 2 diabetes (T2D) in clinical trials, though real-world evidence is limited. We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice.MethodsPeople with T2D initiated on oral semaglutide in secondary care diabetes clinics at two hospital sites in Wales (United Kingdom) were included. Data were collected on reasons for oral semaglutide initiation and changes in bodyweight, blood pressure, glycemic control, and lipid profiles over follow-up at 3–6 months, and at 6–12 months. Data were collected to determine the safety of oral semaglutide.ResultsSeventy-six patients were included, with a median age 59.3 [51.4–67.6] years, and 38 (50.0%) patients were female. The most common reasons for oral semaglutide were need for weight loss and improved glycemia (69.8%), and improved glycemia alone (25.0%). Oral semaglutide associated with significantly reduced bodyweight (− 3.3 kg), body mass index (BMI) (– 0.9 kg/m2), glycated hemoglobin (HbA1c) (− 11 mmol/mol), and total cholesterol (− 0.4 mmol/l) by 3–6 months follow-up. At 6–12 months, there was a significant reduction in systolic blood pressure (− 7.0 mmHg), in addition to sustained reductions in other metabolic parameters. By 12 months, 18 (23.6%) patients had discontinued the drug, largely resulting from gastrointestinal disturbance, but there were no serious events in this cohort.ConclusionsOral semaglutide was effective in improving cardiovascular risk factors in this real-world population living with T2D, and no serious events were identified related to oral semaglutide in this patient group. |
published_date |
2024-05-09T16:28:45Z |
_version_ |
1801669705882140672 |
score |
11.021648 |